Don Morris, one of the founding scientists at Affymetrix and the holder of numerous patents, becomes chief technology officer and vice president of bioinformatics at Lipomics
Lipomics Technologies, a privately held company that develops tools for assessing and understanding complex metabolic conditions using proprietary technologies for lipid metabolite analysis and interpretation, today announced that Macdonald (Don) Morris has joined the company as its chief technology officer (CTO) and vice president of bioinformatics.
One of the founding scientists at Affymetrix in 1992, Morris was lead scientist and then senior scientist at that company from 1993 to 1998 where he developed the original algorithms for chip design and data analysis along with methods to enable high density printing. Morris then worked at Incyte Genomics from 1998 to 2002 holding positions with increasing levels of responsibility as associate director, director and senior director of bioinformatics.
After Incyte, Morris joined Expression Diagnostics as vice president of informatics where he worked to define the company's informatics strategy and R and D plans.
"We are pleased to have Don join us at Lipomics," said Tom Anderson, CEO of Lipomics.
"He has been on the leading edge of informatics and bioinformatics for many years - essentially since the field was born.
"He has an impressive track record of initiating and managing successful interdisciplinary technology projects such as algorithm development for microarrays, database products, genomics, polymorphism analysis, target validation and diagnostics.
"His leadership will be of great benefit as we develop new products to meet our customers' needs". "I am delighted to join such an exceptional company. "Not only do the lipid-based technologies developed by Lipomics generate data of an accuracy that is unparalleled among genomic-era technologies but they have demonstrated clearly superior utility in blockbuster disease areas such as diabetes, obesity, cardiovascular disease, and systemic inflammation," said Don Morris.
"Lipomics has high-content, analytic-quality data and proprietary bioinformatics methods that are cutting through the post-genome confusion and creating opportunities for new treatments to the metabolic diseases of the twenty-first century.
"I look forward to working with this outstanding team to further the development of a rapidly expanding set of clinical research tools and new diagnostics".
Inventor of 13 issued and seven pending US patents, Morris earned both a BSc with honours and a PhD in mathematics from Stanford University prior to completing two years of post doctoral study in pharmaceutical chemistry at UC San Francisco.
He also completed two years at Yale from 1980 to 82 in mathematics.
Morris holds a number of honours and is the author or co-author of numerous published scientific papers and articles.
